Medical Device Authorization Procedure and Preparation Guide
Obtaining medical device authorization in Korea requires navigating a structured regulatory framework administered by the Ministry of Food and Drug Safety (MFDS). Understanding the classification system, choosing the appropriate authorization pathway, and preparing comprehensive documentation are essential for a successful submission. This guide provides a detailed overview.
Classification System
Korea classifies medical devices into four classes based on risk level:
Class I (lowest risk): Simple devices such as surgical instruments, bandages, and examination gloves. Subject to notification rather than approvalClass II (moderate risk): Devices including blood pressure monitors, powered wheelchairs, and ultrasound diagnostic equipment. Require certification by MFDS-recognized bodiesClass III (moderate-high risk): Devices such as orthopedic implants, hemodialysis machines, and some in-vitro diagnostics. Require direct MFDS approvalClass IV (highest risk): Life-sustaining or high-risk devices including cardiac pacemakers, drug-eluting stents, and some combination products. Require the most extensive MFDS reviewClassification determines the regulatory pathway, review timeline, and documentation requirements. An incorrect classification can lead to significant delays, so confirming classification through pre-submission consultation with MFDS is recommended.
Authorization Pathways
Notification (Class I): Manufacturers submit a notification to MFDS or a designated body, providing basic product information. Processing typically takes 15-20 business daysCertification (Class II): Applications are reviewed by MFDS-recognized certification bodies. The review focuses on technical documentation, performance testing, and quality management system complianceApproval (Class III and IV): Full MFDS review including scientific and clinical assessment. Class IV devices undergo the most rigorous evaluation with advisory committee review when neededRequired Documents
A complete technical file for MFDS submission typically includes:
Technical documentation: Product description, design specifications, principles of operation, component materials, and intended use statementPerformance testing: Results of bench testing, electrical safety testing (IEC 60601 series for electrical devices), and software validation for software-containing devicesBiocompatibility: ISO 10993 biocompatibility test reports for devices contacting the body, with specific test selection based on contact type and durationClinical data: Clinical evaluation reports based on clinical investigation data, literature review, or equivalence to predicate devices, depending on risk class and noveltyLabeling and instructions for use: Korean-language labeling, user manuals, and patient information documentsQuality management system: ISO 13485 certification or equivalent quality system documentationMFDS Review Process
Timeline expectations vary by device class and review pathway:
Class I notification: 15-20 business daysClass II certification: 60-90 business daysClass III approval: 90-120 business daysClass IV approval: 120-180 business daysCommon deficiency letters address issues such as incomplete performance testing data, insufficient clinical evidence for claimed indications, biocompatibility testing gaps, and labeling non-compliance. Responding promptly and thoroughly to deficiency letters is critical, as each round of queries can add weeks to the timeline.
Post-Market Requirements
Authorization is only the beginning of regulatory obligations:
Vigilance reporting: Manufacturers must report adverse events and device malfunctions to MFDS within prescribed timelines (serious events within 15 days)Periodic safety update reports: Submit regular safety reports summarizing adverse event data, corrective actions, and ongoing safety assessmentsQuality management: Maintain ISO 13485 compliance and be prepared for periodic MFDS inspections of manufacturing and quality systemsPost-market clinical follow-up: For higher-risk devices, conduct planned post-market clinical studies to confirm long-term safety and performanceProduct changes: Any changes to design, materials, manufacturing, or intended use must be assessed for regulatory impact and may require supplemental submissionsHow KITIM Can Help
KITIM guides medical device companies through the entire authorization process, from pre-submission classification consultation to post-market compliance. Our services include regulatory strategy development, technical file preparation, clinical evaluation support, and quality management system consulting. Contact us to discuss your medical device regulatory needs.
